Egyptian International Pharmaceutical Investments (CAI:PHAR) Other Current Payables: E£911 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
73 GF Score
Price E£90.10
GF Value E£59.92
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Other Current Payables?

Egyptian International Pharmaceutical Investments CAI:PHAR -1.53% 73 Other Current Payables is E£911 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 73/100 and a GF Value™ of E£59.92 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Egyptian International Pharmaceutical Investments's Other Current Payables for the quarter that ended in Mar. 2026 was E£911 Mil.

Egyptian International Pharmaceutical Investments's quarterly Other Current Payables declined from Jun. 2025 (E£467 Mil) to Sep. 2025 (E£238 Mil) but then increased from Sep. 2025 (E£238 Mil) to Mar. 2026 (E£911 Mil).

Egyptian International Pharmaceutical Investments's annual Other Current Payables increased from Dec. 2022 (E£155 Mil) to Dec. 2023 (E£174 Mil) and increased from Dec. 2023 (E£174 Mil) to Dec. 2024 (E£199 Mil).

Egyptian International Pharmaceutical Investments Other Current Payables Related Terms

Egyptian International Pharmaceutical Investments Other Current Payables Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Other Current Payables Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 119.30 154.73 173.76 198.97

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.97 853.95 466.73 237.79 911.18
CAI:PHAR
73GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of E£911 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Other Current Payables of E£911 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Other Current Payables too high?
Egyptian International Pharmaceutical Investments' current Other Current Payables is E£911 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Other Current Payables compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Other Current Payables of E£911 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Other Current Payables is E£911 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.92, compared to a current price of E£90.10 — trading 50.4% above its estimated fair value. The current Other Current Payables is E£911 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 73/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Other Current Payables is E£911 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£90.10 is trading 50.4% above its estimated GF Value™ of E£59.92. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Other Current Payables: E£911 Mil
  • GF Value™: E£59.92 vs. price of E£90.10 (50.4% above fair value)
  • GF Score™: 73/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
73GF Score

Get the complete analysis for CAI:PHAR

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£90.10
Price
E£59.92
GF Value